These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 25975261)

  • 21. Dasatinib promotes paclitaxel-induced necroptosis in lung adenocarcinoma with phosphorylated caspase-8 by c-Src.
    Diao Y; Ma X; Min W; Lin S; Kang H; Dai Z; Wang X; Zhao Y
    Cancer Lett; 2016 Aug; 379(1):12-23. PubMed ID: 27195913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulation of the prometastatic neuregulin-MMP13 axis by SRC family kinases: therapeutic implications.
    Orive-Ramos A; Seoane S; Ocaña A; Pandiella A; Montero JC
    Mol Oncol; 2017 Dec; 11(12):1788-1805. PubMed ID: 29032615
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dasatinib attenuates overexpression of Src signaling induced by the combination treatment of veliparib plus carboplatin in triple-negative breast cancer.
    Sun Y; Lin X; Aske JC; Ye P; Williams C; Abramovitz M; Leyland-Jones BR
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1241-1256. PubMed ID: 31541266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
    Johnson FM; Saigal B; Talpaz M; Donato NJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6924-32. PubMed ID: 16203784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tunicamycin potentiates paclitaxel-induced apoptosis through inhibition of PI3K/AKT and MAPK pathways in breast cancer.
    Huang S; Wang D; Zhang S; Huang X; Wang D; Ijaz M; Shi Y
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):685-696. PubMed ID: 28779263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma.
    Truffaux N; Philippe C; Paulsson J; Andreiuolo F; Guerrini-Rousseau L; Cornilleau G; Le Dret L; Richon C; Lacroix L; Puget S; Geoerger B; Vassal G; Östman A; Grill J
    Neuro Oncol; 2015 Jul; 17(7):953-64. PubMed ID: 25534822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian Cancer.
    Pathak HB; Zhou Y; Sethi G; Hirst J; Schilder RJ; Golemis EA; Godwin AK
    PLoS One; 2015; 10(12):e0144126. PubMed ID: 26637171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthetic paclitaxel-octreotide conjugate reversing the resistance of A2780/Taxol to paclitaxel in xenografted tumor in nude mice.
    Chen X; Zhang XY; Shen Y; Fan LL; Ren ML; Wu YP
    Oncotarget; 2016 Dec; 7(50):83451-83461. PubMed ID: 27825139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo.
    Rosanò L; Di Castro V; Spinella F; Nicotra MR; Natali PG; Bagnato A
    Mol Cancer Ther; 2007 Jul; 6(7):2003-11. PubMed ID: 17620430
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs.
    Puvanenthiran S; Essapen S; Seddon AM; Modjtahedi H
    Int J Oncol; 2016 Nov; 49(5):1825-1838. PubMed ID: 27599579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The combination of dasatinib and gefitinib enhances the killing effect of gefitinib on HCC827 lung cancer cells].
    Wang Z; Li L; Shao Z; Xie H; Yang F; Zhou N
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 May; 32(5):595-9. PubMed ID: 27126935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion.
    Do TV; Xiao F; Bickel LE; Klein-Szanto AJ; Pathak HB; Hua X; Howe C; O'Brien SW; Maglaty M; Ecsedy JA; Litwin S; Golemis EA; Schilder RJ; Godwin AK; Connolly DC
    Oncogene; 2014 Jan; 33(5):539-49. PubMed ID: 23334327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.
    Takahashi R; Mabuchi S; Kawano M; Sasano T; Matsumoto Y; Kuroda H; Kozasa K; Hashimoto K; Sawada K; Kimura T
    PLoS One; 2016; 11(3):e0151050. PubMed ID: 26986199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line.
    Pengetnze Y; Steed M; Roby KF; Terranova PF; Taylor CC
    Biochem Biophys Res Commun; 2003 Sep; 309(2):377-83. PubMed ID: 12951060
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SRC signaling is crucial in the growth of synovial sarcoma cells.
    Michels S; Trautmann M; Sievers E; Kindler D; Huss S; Renner M; Friedrichs N; Kirfel J; Steiner S; Endl E; Wurst P; Heukamp L; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
    Cancer Res; 2013 Apr; 73(8):2518-28. PubMed ID: 23580575
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of SRC/FAK cue: A novel pathway for the synergistic effect of rosuvastatin on the anti-cancer effect of dasatinib in hepatocellular carcinoma.
    El Sayed I; Helmy MW; El-Abhar HS
    Life Sci; 2018 Nov; 213():248-257. PubMed ID: 30292831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting of Wnt/β-Catenin by Anthelmintic Drug Pyrvinium Enhances Sensitivity of Ovarian Cancer Cells to Chemotherapy.
    Zhang C; Zhang Z; Zhang S; Wang W; Hu P
    Med Sci Monit; 2017 Jan; 23():266-275. PubMed ID: 28090074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib.
    Garmendia I; Pajares MJ; Hermida-Prado F; Ajona D; Bértolo C; Sainz C; Lavín A; Remírez AB; Valencia K; Moreno H; Ferrer I; Behrens C; Cuadrado M; Paz-Ares L; Bustelo XR; Gil-Bazo I; Alameda D; Lecanda F; Calvo A; Felip E; Sánchez-Céspedes M; Wistuba II; Granda-Diaz R; Rodrigo JP; García-Pedrero JM; Pio R; Montuenga LM; Agorreta J
    Am J Respir Crit Care Med; 2019 Oct; 200(7):888-899. PubMed ID: 31166114
    [No Abstract]   [Full Text] [Related]  

  • 39. Nuclear expression of Lyn, a Src family kinase member, is associated with poor prognosis in renal cancer patients.
    Roseweir AK; Qayyum T; Lim Z; Hammond R; MacDonald AI; Fraser S; Oades GM; Aitchison M; Jones RJ; Edwards J
    BMC Cancer; 2016 Mar; 16():229. PubMed ID: 26984511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.
    Larsen SL; Laenkholm AV; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
    PLoS One; 2015; 10(2):e0118346. PubMed ID: 25706943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.